RecruitingPhase 2NCT05070845

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA

Sponsor

Pfizer

Enrollment

91 participants

Start Date

Feb 2, 2022

Study Type

INTERVENTIONAL

Conditions

Primary immune thrombocytopenia

Summary

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called PF-06835375 for people with primary immune thrombocytopenia. The study is currently recruiting participants at 31 locations. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALPF-06835375

CXCR5 inhibitor

Locations(31)

East Carolina University

Greenville, North Carolina, United States

Liverpool Hospital

Liverpool, New South Wales, Australia

South West Radiology

Liverpool, New South Wales, Australia

Slade Pharmacy

Mount Kuring-Gai, New South Wales, Australia

Calvary Mater Newcastle

Waratah, New South Wales, Australia

Flinders Medical Centre

Bedford Park, South Australia, Australia

ICON Cancer Centre - Kurralta Park

Kurralta Park, South Australia, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Royal Perth Hospital

Perth, Western Australia, Australia

Unity Health Toronto, St. Michael's Hospital

Toronto, Ontario, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Fakultni nemocnice Hradec Kralove

Hradec Králové, Czechia

Fakultni nemocnice Ostrava

Ostrava - Poruba, Czechia

Fakultni nemocnice Kralovske Vinohrady

Prague, Czechia

Vseobecna fakultni nemocnice v Praze

Prague, Czechia

Pécsi Tudományegyetem Klinikai Központ

Pécs, Baranya, Hungary

Somogy Megyei Kaposi Mór Oktató Kórház

Kaposvár, Somogy County, Hungary

Semmelweis University

Budapest, Hungary

Petz Aladár Egyetemi Oktató Kórház

Győr, Hungary

Tolna Varmegyei Balassa Janos Korhaz

Szekszárd, Hungary

Komárom-Esztergom Vármegyei Szent Borbála Kórház

Tatabánya, Hungary

AIDPORT Sp. z o.o.

Skórzewo, Greater Poland Voivodeship, Poland

InterHem

Bialystok, Poland

Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne

Gdansk, Poland

Pratia Onkologia Katowice

Katowice, Poland

Uniwersytecki Szpital Kliniczny w Poznaniu

Poznan, Poland

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu

Wroclaw, Poland

Addenbrooke's Hospital

Cambridge, Cambridgeshire, United Kingdom

Derriford Hospital

Plymouth, Devon, United Kingdom

The Royal Cornwall Hospital

Truro, England, United Kingdom

Hammersmith Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05070845

Related Trials

A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)

NCT07700238

SG301-SC Injection Safety Study in Subjects With Primary ITP Patients

NCT077102485 locations

A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment

NCT07786077

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

NCT0703942225 locations

Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)

NCT061075821 location